The increasing cases of genetic mutations is fostering the growth of the global acute myeloid leukemia treatment market says fortune business Insights in a report, titled “Acute Myeloid Leukemia Treatment Market Size, Share and Global Trend By Disease Type (Myeloblastic, Promyelocytic, Myelomonocytic), By Treatment Type (Chemotherapy, Targeted Therapy, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography Forecast Till 2026.” Increasing investments in research and development by pharmaceuticals companies are driving the global acute myeloid leukemia treatment market
Some of the major companies that are present in the Global Acute Myeloid Leukemia Treatment Market are
- VERASTEM, INC.
- Genzyme Corporation
- Neomed Management AS
- Sunesis Pharmaceuticals Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- GlaxoSmithKline plc., and others.
FDA Approves XOSPATA®
Astellas Pharma Inc., a Japanese pharmaceutical company launched XOSPATA®, for the treatment of relapsed or refractory acute myeloid leukemia in adult patients. The new drug is FDA approved and will support in the treatment of patients with refractory or relapsed FLT3 mutation-positive (FLT3mut+) acute myeloid leukemia. The acute myeloid leukemia treatment market is predicted to witness high demand during the forecast period, owing to the launch of the advanced drug XOSPATA®. Several market players are launching drugs with FDA approval for the treatment of acute myeloid leukemia. For instance, Genentech, Inc. received FDA approval for the Venclexta for the treatment of patients who are newly-diagnosed with acute myeloid leukemia or patients who are not eligible for intensive induction chemotherapy. The aforementioned factors are contributing significantly to the global acute myeloid leukemia treatment market.
Segmentation for Acute Myeloid Leukemia Treatment Market are;
By Disease Type
By Treatment Type
- Targeted Therapy
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/acute-myeloid-leukemia-treatment-market-100607
Increasing R&D Investments To Contribute Growth
The growing cases of acute myeloid leukemia and unmet needs of patients are leading towards the development of new drugs by pharmaceutical companies, which in turn is fostering the growth of the acute myeloid leukemia treatment market. for instance, Pfizer Inc. launched Cglasdegib (Daurismo) with FDA approval, for patients who are newly-diagnosed with acute myeloid leukemia (AML). In 2019, according to the American Cancer Society, the number of new acute myeloid leukemia cases in the U.S estimated to be 21,450.
The rising prevalence of genetic mutation, high exposure to radiations and sedentary lifestyles are some of the factors encouraging the cases of acute myeloid leukemia across the globe. In addition, product launches and rising investments in research and development activities by pharmaceutical companies are also predicted to foster growth for the global acute myeloid leukemia treatment market in the forthcoming year. Nonetheless, high risks of side effects associated with the use of drugs and expensive cost of stem cell transplantation are the factors restraining the growth of the global acute myeloid leukemia treatment market.
North America to Dominate the Global Market
Geographically, the global acute myeloid leukemia treatment market is segmented into North America, Europe, Asia- Pacific, Latin America, Middle East & Africa. North America is expected to dominate the global acute myeloid leukemia treatment market during the forecast period. Strategic research and development, excellent health reimbursement policies along with growing demand for advanced treatment is boosting the market in the region.
In Europe, the acute myeloid leukemia treatment market is predicted to grow at a significant rate, owing to the rising incidences of disease and active government aid. Asia Pacific is expected to grow at a remarkable CAGR during the forecast period owing to the increasing government expenditure for the treatment of cancer and developing healthcare infrastructure. In addition, rising inclination towards targeted therapies is expected to boost the growth of the global acute myeloid leukemia treatment market in the region in the forthcoming year.
KEY QUESTIONS ANSWERED:
What is the market size and growth rate of the global and regional market by various segments?
What is the market size and growth rate of the market for selective countries?
Which region or sub-segment is expected to drive the market in the forecast period?
What Factors are estimated to drive and restrain the market growth?
What are the key technological and market trends shaping the market?
What are the key opportunities in the market?
What are the key companies operating in the market?
Which company accounted for the highest market share?
Why Choose Fortune Business Insights?
More Trending Topics from Fortune Business Insights:
Hops Market Is Expected to Grow; The Acquisition and Partnership of Key Players to Launch Hop Products Will Promote Growth